Endpoints and clinical trial design for nonalcoholic steatohepatitis

J. Sanyal, Arun; M. Brunt, Elizabeth; E. Kleiner, David; V. Kowdley, Kris; Chalasani, Naga; E. Lavine, Joel; Ratziu, Vlad; J. McCullough, Arthur

doi:10.1002/hep.24376

Public

Endpoints and clinical trial design for nonalcoholic steatohepatitis

Published in Hepatology • Apr 21, 2011

Authors:

Arun J. Sanyal

Elizabeth M. Brunt

David E. Kleiner

Abstract

UNLABELLED: Nonalcoholic fatty liver disease is a common cause of chronic liver disease in the general population. Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease, is associated with an increased risk of liver-related mortality and cardiovascular disease....

Subject

Nonalcoholic steatohepatitis

Nonalcoholic fatty liver disease

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!